Enumeration & Molecular Characterization of Circulating Tumour Cells in

Clinical Trial Summary

Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial. In connection to treatment, blood samples for determination and enumeration of circulating tumour cells will be collected at different time points. Serum and plasma will be collected and stored for future analysis of RNA and DNA.

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04872608` - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer	Phase 1
Terminated	`NCT02202746` - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT02506556` - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer	Phase 2
Recruiting	`NCT05534438` - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	Phase 2
Recruiting	`NCT03368729` - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Completed	`NCT04103853` - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer	Phase 1
Terminated	`NCT01847599` - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib	N/A
Active, not recruiting	`NCT03147287` - Palbociclib After CDK and Endocrine Therapy (PACE)	Phase 2
Not yet recruiting	`NCT06062498` - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT04095390` - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT04432454` - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 2
Recruiting	`NCT03323346` - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05744375` - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Phase 2
Completed	`NCT02924883` - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy	Phase 2
Completed	`NCT01942135` - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Phase 3
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Completed	`NCT01401959` - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy	Phase 2
Terminated	`NCT04720664` - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	Phase 2

NCT number	NCT01322893
Study type	Observational
Source	Lund University Hospital
Contact
Status	Completed
Phase
Start date	March 2011
Completion date	June 2016

Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer — CTC-MBC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms